Elevation Oncology, Inc. (ELEV)
Market Cap | 152.99M |
Revenue (ttm) | n/a |
Net Income (ttm) | -39.35M |
Shares Out | 54.64M |
EPS (ttm) | -0.98 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 742,304 |
Open | 2.860 |
Previous Close | 2.860 |
Day's Range | 2.740 - 2.920 |
52-Week Range | 0.363 - 5.830 |
Beta | 1.53 |
Analysts | Strong Buy |
Price Target | 7.80 (+178.57%) |
Earnings Date | Aug 1, 2024 |
About ELEV
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ELEV stock is "Strong Buy." The 12-month stock price forecast is $7.8, which is an increase of 178.57% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/e/d/press9-2499430.jpg)
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination por...
![](https://cdn.snapi.dev/images/v1/x/e/conf9-2414318.jpg)
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ac...
![](https://cdn.snapi.dev/images/v1/z/q/press7-2405726.jpg)
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented pr...
![](https://cdn.snapi.dev/images/v1/j/d/press4-2361949.jpg)
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and deve...
![](https://cdn.snapi.dev/images/v1/o/a/press7-2310597.jpg)
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 -- -- Preclinical proof-of...
![](https://cdn.snapi.dev/images/v1/e/6/conf16-2309741.jpg)
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNews...
![](https://cdn.snapi.dev/images/v1/c/z/press18-2306000.jpg)
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D.
BOSTON , March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...
![](https://cdn.snapi.dev/images/v1/n/q/press4-2300941.jpg)
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
PHILADELPHIA , Feb. 29, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Elevation Oncology, Inc. (NYSE: ELEV) on behalf of the company's investors. The investigation seeks to d...
![](https://cdn.snapi.dev/images/v1/b/p/conf17-2298178.jpg)
Elevation Oncology to Participate in Upcoming Investor Conferences
BOSTON , Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...
![](https://cdn.snapi.dev/images/v1/r/q/press20-2288225.jpg)
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
-- On track to provide update from ongoing Phase 1 clinical trial in mid-2024; additional data expected in 1H 2025 -- BOSTON , Feb. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an...
![](https://cdn.snapi.dev/images/v1/l/i/press19-2238069.jpg)
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
BOSTON , Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...
![](https://cdn.snapi.dev/images/v1/b/o/press4-2217963.jpg)
Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones
-- Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 -- -- Expanding EO-3021 Clinical Development Program to Include Combination Strategy -- -- Announcing HER3-targeting ADC...
![](https://cdn.snapi.dev/images/v1/p/v/conf19-2168606.jpg)
Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference
BOSTON , Nov. 22, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...
![](https://cdn.snapi.dev/images/v1/x/t/press15-2135756.jpg)
Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements
-- Enrollment is ongoing in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2; preliminary safety and anti-tumor activity data expecte...
![](https://cdn.snapi.dev/images/v1/q/0/conf17-2049005.jpg)
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patient...
![](https://cdn.snapi.dev/images/v1/n/w/press19-2025019.jpg)
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021
NEW YORK, Aug. 16, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients...
![](https://cdn.snapi.dev/images/v1/i/o/press16-2004092.jpg)
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements
Initial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refract...
![](https://cdn.snapi.dev/images/v1/o/a/press3-1969826.jpg)
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer
NEW YORK , July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patient...
![](https://cdn.snapi.dev/images/v1/v/a/press19-1927577.jpg)
Elevation Oncology Announces Pricing of $50 Million Public Offering
NEW YORK , June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients...
![](https://cdn.snapi.dev/images/v1/8/g/press11-1927266.jpg)
Elevation Oncology Announces Launch of Proposed Public Offering
NEW YORK , June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients...
![](https://cdn.snapi.dev/images/v1/u/d/press3-1919758.jpg)
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation Onco...
![](https://cdn.snapi.dev/images/v1/s/s/press6-1889673.jpg)
Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements
Partner CSPC Pharmaceutical Group Limited's ongoing Phase 1 SYSA1801 (EO-3021) clinical trial data selected for poster presentation and poster discussion at ASCO 2023 Presented EO-3021 preclinical pro...
![](https://cdn.snapi.dev/images/v1/m/l/press8-1856179.jpg)
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patien...
![](https://cdn.snapi.dev/images/v1/p/r/press17-1839772.jpg)
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023
NEW YORK, April 17, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patient...
![](https://cdn.snapi.dev/images/v1/g/r/conf17-1796916.jpg)
Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023
- Company plans to highlight preclinical proof-of-concept data for EO-3021 in an oral presentation at the New Drugs on the Horizon special session NEW YORK , March 14, 2023 /PRNewswire/ -- Elevation ...